MA vs PFE: Which Is the Better Buy?
Side-by-side comparison of Mastercard Incorporated and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-13.
Mastercard Incorporated · Financial Services
$499.81
+5.0% upside to fair value
Grade B+
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MA |
PFE |
| Current Price |
$499.81 |
$26.33 |
| Fair Value Estimate |
$525.00 |
$33.85 |
| Upside to Fair Value |
+5.0%
|
+28.6%
|
| Market Cap |
$441.6B |
$149.8B |
| Forward P/E |
28.6x
|
19.3x
|
| EV / EBITDA |
21.3x
|
12.9x
|
| Price / Sales |
13.0x
|
2.4x
|
| Price / FCF |
24.9x
|
16.5x
|
| Revenue Growth YoY |
+15.8%
|
-1.2%
|
| Gross Margin |
83.0%
|
70.3%
|
| Operating Margin |
59.4%
|
24.7%
|
| Return on Equity |
206.1%
|
8.7%
|
| Dividend Yield |
0.6% |
0% |
| FCF Yield |
4.01%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Mastercard is one of two global payment network duopolists alongside Visa, with structurally high margins (83% gross, 59% operating, 46% net), powerful network effects, and durable secular tailwinds from the ongoing cash-to-card and card-to-digital migration. Q1 2026 results reported April 30 showed revenue of $8.40 billion (+15.8% YoY) and EPS of $4.35 (+20.8% YoY), driven by continued cross-bor…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
MA |
PFE |
| Zone Low |
$393.75 |
$25.39 |
| Zone High |
$446.25 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|